[go: up one dir, main page]

BRPI0510606A - antagonistas do receptor crth2 - Google Patents

antagonistas do receptor crth2

Info

Publication number
BRPI0510606A
BRPI0510606A BRPI0510606-0A BRPI0510606A BRPI0510606A BR PI0510606 A BRPI0510606 A BR PI0510606A BR PI0510606 A BRPI0510606 A BR PI0510606A BR PI0510606 A BRPI0510606 A BR PI0510606A
Authority
BR
Brazil
Prior art keywords
receptor antagonists
crth2 receptor
crth2
compounds
formula
Prior art date
Application number
BRPI0510606-0A
Other languages
English (en)
Inventor
David Andrew Sandham
Katharine Louise Turner
Catherine Leblanc
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0510606A publication Critical patent/BRPI0510606A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/10—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond
    • C07C67/11—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with ester groups or with a carbon-halogen bond being mineral ester groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/708—Ethers
    • C07C69/712—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ANTAGONISTAS DO RECEPTOR CRTH2. A presente invenção refere-se a compostos da fórmula (I) em forma livre ou de sal, onde R¬ 1¬, R¬ 2¬, R¬ 3¬, X, Y, Z, m e n são conforme descritos no relatório descritivo, processo para preparação deles e seus usos como produto farmacêutico.
BRPI0510606-0A 2004-05-04 2005-05-03 antagonistas do receptor crth2 BRPI0510606A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409921.4A GB0409921D0 (en) 2004-05-04 2004-05-04 Organic compounds
PCT/EP2005/004783 WO2005105727A1 (en) 2004-05-04 2005-05-03 Crth2 receptor antagonists

Publications (1)

Publication Number Publication Date
BRPI0510606A true BRPI0510606A (pt) 2007-10-30

Family

ID=32482645

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510606-0A BRPI0510606A (pt) 2004-05-04 2005-05-03 antagonistas do receptor crth2

Country Status (12)

Country Link
US (1) US20080269335A1 (pt)
EP (1) EP1756032A1 (pt)
JP (1) JP2007536311A (pt)
KR (1) KR20070015562A (pt)
CN (1) CN1950323A (pt)
AU (1) AU2005238199B2 (pt)
BR (1) BRPI0510606A (pt)
CA (1) CA2563454A1 (pt)
GB (1) GB0409921D0 (pt)
MX (1) MXPA06012664A (pt)
RU (1) RU2006142738A (pt)
WO (1) WO2005105727A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
WO2006056752A1 (en) 2004-11-23 2006-06-01 Astrazeneca Ab Phenoxyacetic acid derivatives useful for treating respiratory diseases
WO2007039736A1 (en) 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
US20080293775A1 (en) * 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
CN101970405A (zh) 2007-12-14 2011-02-09 普尔马金医疗(哮喘)有限公司 吲哚及其治疗用途
AU2009210446C1 (en) 2008-02-01 2013-01-10 Brickell Biotech, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
CN102076661B (zh) 2008-07-03 2014-04-09 潘米拉制药公司 前列腺素d2受体的拮抗剂
US8378107B2 (en) 2008-10-01 2013-02-19 Panmira Pharmaceuticals, Llc Heteroaryl antagonists of prostaglandin D2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
WO2011002814A2 (en) * 2009-06-30 2011-01-06 Ligand Pharmaceuticals Inc. Biaryl oxyacetic acid compounds
SG178109A1 (en) 2009-07-31 2012-03-29 Panmira Pharmaceuticals Llc Ophthalmic pharmaceutical compositions of dp2 receptor antagonists
JP2013501052A (ja) 2009-08-05 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２アンタゴニストおよびその用途
SG182398A1 (en) 2010-01-06 2012-08-30 Panmira Pharmaceuticals Llc Dp2 antagonist and uses thereof
AU2011275417A1 (en) 2010-07-05 2013-02-21 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
CN104114169A (zh) 2011-12-16 2014-10-22 阿托佩斯治疗有限公司 用于治疗嗜酸细胞性食管炎的crth2拮抗剂和质子泵抑制剂的组合物
TW201331179A (zh) 2011-12-21 2013-08-01 Actelion Pharmaceuticals Ltd 雜環衍生物及其作為前列腺素ｄ２受體調節劑之用途
CA2876808A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
KR102722949B1 (ko) 2015-06-15 2024-10-28 엔엠디 파마 에이/에스 신경근 장애의 치료에 사용하기 위한 화합물
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
TW201927738A (zh) 2017-12-14 2019-07-16 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
TWI794369B (zh) 2017-12-14 2023-03-01 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
TWI780281B (zh) 2017-12-14 2022-10-11 丹麥商Ｎｍｄ藥品公司 用於治療神經肌肉病症的化合物
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
WO2020233713A1 (zh) * 2019-05-22 2020-11-26 石药集团中奇制药技术（石家庄）有限公司 杂环化合物及其盐的应用
WO2020254559A1 (en) 2019-06-19 2020-12-24 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2039489C3 (de) * 1970-08-08 1979-08-09 Agfa-Gevaert Ag, 5090 Leverkusen Farbfotografisches Aufzeichnungsmaterial
DE2039490A1 (de) * 1970-08-08 1972-02-24 Agfa Gevaert Ag Fotografisches farbkupplerhaltiges Material
CH585687A5 (pt) * 1972-08-24 1977-03-15 Ciba Geigy Ag
DE2503223A1 (de) * 1974-02-05 1975-08-07 Sandoz Ag Verfahren zur herstellung neuer carbocyclischer verbindungen
FR2567514B1 (fr) * 1984-07-13 1987-08-28 Najer Henry Nouveaux ether-oxydes derives de cyclopropylphenols
KR100340273B1 (ko) * 1997-10-14 2002-06-14 야마모토 카즈모토 비페닐-5-알칸산 유도체 및 이의 용도
JPH11263752A (ja) * 1998-01-12 1999-09-28 Honshu Chem Ind Co Ltd ヒドロ芳香族オキシ酢酸ｔ―ブチルエステル
EP1077929A1 (en) * 1998-05-12 2001-02-28 American Home Products Corporation 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia
AU2003211384B2 (en) * 2002-02-21 2008-12-11 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivative and use thereof
US6867320B2 (en) * 2002-02-21 2005-03-15 Asahi Kasei Pharma Corporation Substituted phenylalkanoic acid derivatives and use thereof
WO2004094386A1 (en) * 2003-03-28 2004-11-04 Eli Lilly And Company Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b)
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
CN101031539A (zh) * 2003-08-14 2007-09-05 旭化成制药株式会社 取代的芳基链烷酸衍生物及其用途

Also Published As

Publication number Publication date
AU2005238199A1 (en) 2005-11-10
AU2005238199B2 (en) 2009-03-26
KR20070015562A (ko) 2007-02-05
CA2563454A1 (en) 2005-11-10
GB0409921D0 (en) 2004-06-09
CN1950323A (zh) 2007-04-18
EP1756032A1 (en) 2007-02-28
MXPA06012664A (es) 2007-01-16
US20080269335A1 (en) 2008-10-30
WO2005105727A1 (en) 2005-11-10
JP2007536311A (ja) 2007-12-13
RU2006142738A (ru) 2008-06-10

Similar Documents

Publication Publication Date Title
BRPI0510606A (pt) antagonistas do receptor crth2
BRPI0510453A (pt) composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
MX2010008719A (es) Pirrolo [2,-d] piridinas y usos de las mismas como inhibidores de cinasa de tirosina.
BRPI0514691A (pt) composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, composição farmacêutica, e, uso de um composto ou um sal farmaceuticamente aceitável do mesmo
WO2007025709A3 (en) Organic compounds
ECSP066914A (es) FORMA CRISTALINA dd DEL CLORHIDRATO DE LA IVABRADINA, SU PROCEDIMIENTO DE PREPARACIÓN Y LAS COMPOSICIONES FARMACÉUTICAS QUE LA CONTIENEN
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
CO6331340A2 (es) Pirrolo-pirimidinas y pirrolo piridinas
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BRPI0512330A (pt) derivados de pirazol-pirimidina
BRPI0607927A2 (pt) derivados de pirazol-pirimidina
EA201070841A1 (ru) НОВЫЕ ПИРАЗОЛО[3,4-d]ПИРИМИДИНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ПРОТИВОРАКОВЫХ ЛЕКАРСТВЕННЫХ СРЕДСТВ
SE0401762D0 (sv) Novel compounds
UA104988C2 (uk) Похідні піроніндолу та спосіб їх отримання
CY1109460T1 (el) Υποκατεστημενες ενωσεις 5,6,7,8-τετραϋδρο-ιμιδαζο[1,2-α]-πυριδιν-2-υλαμινης και η χρησιμοποιηση τους για την παρασκευη φαρμακων
MY154962A (en) Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-ht2a seratonin receptor
ECSP11010765A (es) NUEVOS DERIVADOS DE IMIDAZO[1,2-a]PIRIMIDINA, SU PROCEDIMIENTO DE PREPARACIÓN, SU APLICACIÓN COMO MEDICAMENTOS, COMPOSICIONES FARMACÉUTICAS Y NUEVA UTILIZACIÓN PARTICULARMENTE COMO INHIBIDORES DE MET
BRPI0607583A2 (pt) derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
BRPI0511778A (pt) derivados da naftalina úteis como ligantes do receptor 3 da histamina
BR0308419A (pt) Derivados de azetidina como antagonistas do receptor ccr-3
BRPI0508969A (pt) compostos orgánicos
BRPI0409570A (pt) derivados de 3-benzidrilideno-8-aza-biciclo[3.2.1]octano com atividade receptora de opióides
BRPI0416745A (pt) novos compostos
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
BRPI0416739A (pt) derivados de indano substituìdo heterocìclico e compostos afins para o tratamento de esquizofrenia

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.